Related Experiment Video
Updated: Mar 25, 2026
07:15
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
Published on: July 28, 2020
10.4K
Long-Term Clinical Responses of Neoadjuvant Dendritic Cell Infusions and Radiation in Soft Tissue Sarcoma
Shailaja Raj1, Marilyn M Bui1, Gregory Springett1
1H. Lee. Moffitt Cancer Center, Tampa, FL 33612, USA.
Sarcoma
|February 17, 2016
Summary
Neoadjuvant radiation combined with dendritic cell (DC) injections shows promise for high-risk soft tissue sarcomas (STS). This approach demonstrated safety and encouraging survival rates, with 61% of patients alive and recurrence-free for 2-8 years.
Area of Science:
- Oncology
- Immunotherapy
- Surgical Oncology
Background:
- High-grade soft tissue sarcomas (STS) >5cm carry a high risk of distant metastasis.
- Dendritic cell (DC) vaccines have previously demonstrated consistent immunogenicity.
Purpose of the Study:
- To evaluate the safety and immunological response of neoadjuvant radiation combined with DC injections in high-risk STS patients.
- To assess preliminary clinical outcomes, including survival and recurrence rates.
Main Methods:
- Phase I, single-institution study involving 18 newly diagnosed high-risk STS patients.
- Neoadjuvant treatment: 50 Gy external beam radiation (EBRT) in 25 fractions, combined with four intratumoral DC injections.
- Treatment was followed by complete surgical resection.
Main Results:
- No unexpected toxicities or serious adverse events were observed, indicating good clinical safety.
- Encouraging survival outcomes: 12/18 (67%) patients alive at 2-8 years.
- High rate of disease control: 11/18 (61%) patients alive with no systemic recurrence.
Conclusions:
- Neoadjuvant dendritic cell injections combined with radiation therapy are clinically supported for sarcoma treatment.
- Optimal combination therapy may improve clinical outcomes in soft tissue sarcoma.
- Favorable immunological responses showed correlation with clinical outcomes in some patients.
